File:Considerations for the design of engineered live bacterial therapeutics.pdf
From WikiMD's WELLNESSPEDIA
Size of this JPG preview of this PDF file: 375 × 600 pixels.
Original file (750 × 1,200 pixels, file size: 394 KB, MIME type: application/pdf)
Summary[edit]
| Summary | |
|---|---|
| Description | a Several aspects require consideration during the design of an engineered bacterial therapeutic. The selection of a chassis organism can be guided by the desired site of activity and pharmacokinetic properties of the chassis, as well as manufacturing feasibility. The design of genetic circuits may also be influenced by the circuit’s effectors, pragmatic concerns regarding inducer compounds, and the genetic stability of regulatory circuits. Critically, the design of an engineered bacterial drug may also be constrained by considerations for the needs of patients. b Optimal strain design often requires a balance between strain suitability for function in the target microenvironment and concerns for feasibility of manufacturing and clinical development.[1] |
| Source | Wikimedia Commons |
| Author | Mark R. Charbonneau, Vincent M. Isabella, Ning Li & Caroline B. Kurtz |
| Permission | See Commons |
Licensing[edit]
Creative Commons Attribution 4.0 International (CC BY 4.0)
This file is licensed under the Creative Commons Attribution 4.0 International license.
You may share and adapt the material provided appropriate attribution is given.
Official license: CC BY 4.0
Original attribution and file history: Wikimedia Commons
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 01:22, 2 June 2026 |  | 750 × 1,200 (394 KB) | Maintenance script (talk | contribs) | == Summary == Importing file |
You cannot overwrite this file.
File usage
The following 2 pages use this file:
